Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) has been assigned a $9.00 target price by analysts at HC Wainwright in a research note issued to investors on Friday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price objective would indicate a potential upside of 96.51% from the company’s previous close.

PIRS has been the topic of several other research reports. BidaskClub lowered Pieris Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 26th. TheStreet upgraded Pieris Pharmaceuticals from a “d” rating to a “c-” rating in a report on Wednesday, May 3rd. Finally, Rodman & Renshaw began coverage on Pieris Pharmaceuticals in a report on Tuesday, May 30th. They set a “buy” rating and a $9.00 price target on the stock. Five investment analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and a consensus target price of $8.25.

Shares of Pieris Pharmaceuticals (NASDAQ:PIRS) traded down 1.08% on Friday, hitting $4.58. 642,686 shares of the stock traded hands. The firm has a market cap of $197.26 million, a PE ratio of 9.96 and a beta of 1.79. The firm has a 50 day moving average price of $5.35 and a 200 day moving average price of $3.57. Pieris Pharmaceuticals has a 52-week low of $1.30 and a 52-week high of $6.20.

Pieris Pharmaceuticals (NASDAQ:PIRS) last released its quarterly earnings results on Wednesday, May 10th. The biotechnology company reported ($0.19) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.16 by $0.35. Pieris Pharmaceuticals had a negative net margin of 459.73% and a negative return on equity of 123.78%. The company had revenue of $1.34 million for the quarter, compared to analysts’ expectations of $32.30 million. On average, equities analysts forecast that Pieris Pharmaceuticals will post ($0.70) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece was reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/08/13/pieris-pharmaceuticals-inc-nasdaqpirs-given-a-9-00-price-target-by-hc-wainwright-analysts.html.

A number of hedge funds have recently added to or reduced their stakes in the company. State of Wisconsin Investment Board acquired a new stake in Pieris Pharmaceuticals during the second quarter worth $132,000. Creative Planning raised its stake in Pieris Pharmaceuticals by 29.6% in the first quarter. Creative Planning now owns 60,000 shares of the biotechnology company’s stock worth $156,000 after buying an additional 13,700 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in Pieris Pharmaceuticals during the second quarter worth $162,000. Rhumbline Advisers acquired a new stake in Pieris Pharmaceuticals during the second quarter worth $184,000. Finally, Schwab Charles Investment Management Inc. acquired a new stake in Pieris Pharmaceuticals during the second quarter worth $292,000. Institutional investors and hedge funds own 44.88% of the company’s stock.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

Receive News & Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.